3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
9
Breast
9
Genitourinary
7
Thoracic
6
Gynecologic
5
Lymphoid
3
Classical hematology
3
Other hematologic neoplasm
2
Dermatologic
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
Head & Neck
1
CNS
1
Conditions
Melanoma
1
Carcinoma, Merkel Cell
1
Interventions
Dacarbazine
27
Nivolumab
26
pembrolizumab
22
Ipilimumab
20
3-ingenyl angelate
11
Interferon-alpha
10
Imiquimod
10
Temozolomide
9
trametinib
8
Vemurafenib
8
Photochemotherapy
8
Aminolevulinic Acid
8
methyl 5-aminolevulinate
7
dabrafenib
7
cemiplimab
7
aldesleukin
7
Introns
7
Surgical Procedures, Operative
6
Radiotherapy
6
Interferon alpha-2
6
Fluorouracil
6
Paclitaxel
5
Melphalan
5
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
binimetinib
4
Specimen Handling
4
Opdualag
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Saline Solution
×
Dermatologic
×
Clear all
NCT03271372
2026-05-12
ADAM
University of Washington
Phase 3
Active not recruiting
101 enrolled
NCT05933577
2025-09-24
V940-001
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
1,089 enrolled